封面
市場調查報告書
商品編碼
1732841

新生兒篩檢市場-全球產業規模、佔有率、趨勢、機會和預測(按技術、按檢測類型、按最終用戶、按地區和按競爭分類,2020-2030 年)

Newborn Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Technology, By Test Type, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球新生兒篩檢市場價值為 8.5415 億美元,預計到 2030 年將達到 13.4511 億美元,預測期內複合年成長率為 7.86%。該市場涵蓋新生兒遺傳、代謝和先天性疾病的早期檢測和診斷,通常是在出生後的頭幾天內。由於先天性疾病在全球嬰兒發病率和死亡率中佔很大比例,新生兒篩檢已成為公共醫療保健系統的重要組成部分。政府措施的增加、篩檢技術的進步以及對早期疾病檢測認知的提高顯著提高了採用率。各國正在擴大新生兒篩檢範圍,以涵蓋更廣泛的疾病,而次世代定序和串聯質譜等創新技術則提高了診斷的準確性和效率。先天性疾病的盛行率不斷上升,尤其是在發展中地區,預計這將維持市場成長,這得益於私人檢測計劃、醫療保健支出的增加以及標準化篩檢實踐的全球合作。

市場概覽
預測期 2026-2030
2024年市場規模 8.5415億美元
2030年市場規模 13.4511億美元
2025-2030 年複合年成長率 7.86%
成長最快的領域 醫院
最大的市場 北美洲

關鍵市場促進因素

技術進步

主要市場挑戰

教育和意識

主要市場趨勢

私人測試的興起

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:COVID-19 對全球新生兒篩檢市場的影響

第5章:顧客之聲

第6章:全球新生兒篩檢市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依技術(串聯質譜法、脈搏血氧儀、酵素法測定、DNA測定和其他技術)
    • 依測試類型(乾血斑、聽力篩檢、嚴重先天性心臟缺陷 (CCHD) 和其他測試類型)
    • 按最終使用者(醫院、診斷中心和其他最終使用者)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第7章:亞太地區新生兒篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第8章:歐洲新生兒篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第9章:北美新生兒篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第10章:南美洲新生兒篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章:中東和非洲新生兒篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章:市場動態

  • 驅動程式
  • 挑戰

第13章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 14 章:全球新生兒篩檢市場:SWOT 分析

第 15 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章: 大環境分析

第 17 章:競爭格局

  • Bio-Rad Laboratories Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic Inc.
  • Natus Medical Incorporated
  • PerkinElmer Inc.
  • Trivitron Healthcare
  • ZenTech SA
  • Demant A/S
  • Hill-Rom Holdings Inc.

第 18 章:策略建議

第19章調查會社について,免責事項

簡介目錄
Product Code: 16285

The Global Newborn Screening Market was valued at USD 854.15 million in 2024 and is projected to reach USD 1345.11 million by 2030, growing at a CAGR of 7.86% during the forecast period. This market encompasses the early detection and diagnosis of genetic, metabolic, and congenital conditions in newborns, typically within the first days after birth. As congenital disorders continue to account for a significant share of infant morbidity and mortality globally, newborn screening has become a vital component of public healthcare systems. Increased government initiatives, advancements in screening technologies, and rising awareness regarding early disease detection have significantly boosted adoption rates. Countries are expanding their newborn screening panels to include a broader array of conditions, while innovations such as next-generation sequencing and tandem mass spectrometry have improved diagnostic accuracy and efficiency. The growing prevalence of congenital conditions, particularly in developing regions, is expected to sustain market growth, supported by private testing initiatives, increased healthcare spending, and global collaborations to standardize screening practices.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 854.15 Million
Market Size 2030USD 1345.11 Million
CAGR 2025-20307.86%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

Advancements in Technology

Technological innovations have transformed newborn screening, enabling earlier and more precise detection of a wide array of conditions. Next-Generation Sequencing (NGS) facilitates simultaneous analysis of multiple genes, significantly expanding screening capabilities. It has become instrumental in identifying rare and complex genetic conditions with high accuracy. Similarly, Tandem Mass Spectrometry (MS/MS) has revolutionized metabolic screening by allowing multiple analytes to be tested from a single sample, enabling detection of amino acid and fatty acid disorders efficiently. Multiplex assays and enhanced dried blood spot (DBS) technologies have also contributed to the broader and faster adoption of screening for lysosomal storage and immunodeficiency disorders. These technological advancements have reduced false positives, improved patient outcomes, and lowered healthcare costs through early interventions.

Key Market Challenges

Education and Awareness

Despite technological progress, limited public and professional awareness about the significance of newborn screening remains a substantial barrier. Many parents may lack understanding of the benefits and procedures involved, leading to hesitation or refusal of screening. Inconsistent training and knowledge dissemination among healthcare professionals can further impair effective communication with families. Cultural and language differences, especially in diverse or low-resource regions, exacerbate the issue, hindering outreach and engagement. Additionally, varying policies and resource availability across countries contribute to disparities in screening coverage and effectiveness. Efforts to improve education, standardize procedures, and address misinformation are crucial to increasing participation and acceptance globally.

Key Market Trends

Rise in Private Testing

There is a growing trend toward private newborn screening services, as parents increasingly seek broader testing panels than those offered by public health programs. Personalized medicine, rapid result delivery, and advanced technologies are driving demand for private services. These centers offer greater autonomy and confidentiality, along with supplemental services like genetic counseling and family health planning. In regions with limited or inconsistent public programs, private testing ensures continued access to comprehensive screening. Additionally, private providers often serve mobile populations seeking continuity of care across borders. As awareness grows and disposable incomes rise, private newborn screening is expected to gain further traction, especially in urban and high-income segments.

Key Market Players

  • Bio-Rad Laboratories Inc.
  • GE Healthcare
  • Masimo Corporation
  • Medtronic Inc.
  • Natus Medical Incorporated
  • PerkinElmer Inc.
  • Trivitron Healthcare
  • ZenTech SA
  • Demant A/S
  • Hill-Rom Holdings Inc.

Report Scope

In this report, the Global Newborn Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Newborn Screening Market, By Technology:

  • Tandem Mass Spectrometry
  • Pulse Oximetry
  • Enzyme Based Assays
  • DNA Assays
  • Other Technologies

Newborn Screening Market, By Test Type:

  • Dried Blood Spot
  • Hearing Screening
  • Critical Congenital Heart Defect (CCHD)
  • Other Test Types

Newborn Screening Market, By End User:

  • Hospitals
  • Diagnostic Centers
  • Other End Users

Newborn Screening Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Newborn Screening Market.

Available Customizations

Global Newborn Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Newborn Screening Market

5. Voice of Customer

6. Global Newborn Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assays, DNA Assays, and Other Technologies)
    • 6.2.2. By Test Type (Dried Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), and Other Test Types)
    • 6.2.3. By End User (Hospitals, Diagnostic Centers, and Other End Users),
    • 6.2.4. By Region
    • 6.2.5. By Company (2024)
  • 6.3. Market Map

7. Asia Pacific Newborn Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Test Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Asia Pacific: Country Analysis
    • 7.3.1. China Newborn Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By End User
    • 7.3.2. India Newborn Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Australia Newborn Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Japan Newborn Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By End User
    • 7.3.5. South Korea Newborn Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By End User

8. Europe Newborn Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Test Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Newborn Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Newborn Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Spain Newborn Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Newborn Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Test Type
        • 8.3.4.2.3. By End User
    • 8.3.5. United Kingdom Newborn Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Test Type
        • 8.3.5.2.3. By End User

9. North America Newborn Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Test Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Newborn Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Mexico Newborn Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Canada Newborn Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By End User

10. South America Newborn Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Test Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Newborn Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Newborn Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Newborn Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Newborn Screening Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Technology
    • 11.2.2. By Test Type
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Newborn Screening Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Technology
        • 11.3.1.2.2. By Test Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Newborn Screening Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Technology
        • 11.3.2.2.2. By Test Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Newborn Screening Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Technology
        • 11.3.3.2.2. By Test Type
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Global Newborn Screening Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

  • 17.1. Bio-Rad Laboratories Inc.
    • 17.1.1. Business Overview
    • 17.1.2. Company Snapshot
    • 17.1.3. Products & Services
    • 17.1.4. Financials (As Reported)
    • 17.1.5. Recent Developments
    • 17.1.6. Key Personnel Details
    • 17.1.7. SWOT Analysis
  • 17.2. GE Healthcare
  • 17.3. Masimo Corporation
  • 17.4. Medtronic Inc.
  • 17.5. Natus Medical Incorporated
  • 17.6. PerkinElmer Inc.
  • 17.7. Trivitron Healthcare
  • 17.8. ZenTech SA
  • 17.9. Demant A/S
  • 17.10. Hill-Rom Holdings Inc.

18. Strategic Recommendations

19. About Us & Disclaimer